Guangzhou Baiyunshan Pharmaceutical Stock Cash And Equivalents
| GU5 Stock | EUR 2.12 0.02 0.95% |
Guangzhou Baiyunshan Pharmaceutical fundamentals help investors to digest information that contributes to Guangzhou Baiyunshan's financial success or failures. It also enables traders to predict the movement of Guangzhou Stock. The fundamental analysis module provides a way to measure Guangzhou Baiyunshan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Guangzhou Baiyunshan stock.
Guangzhou |
Guangzhou Baiyunshan Pharmaceutical Company Cash And Equivalents Analysis
Guangzhou Baiyunshan's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Guangzhou Baiyunshan Cash And Equivalents | 21.69 B |
Most of Guangzhou Baiyunshan's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Guangzhou Baiyunshan Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Guangzhou Baiyunshan Pharmaceutical has 21.69 B in Cash And Equivalents. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash and equivalents for all Germany stocks is significantly lower than that of the firm.
Guangzhou Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Guangzhou Baiyunshan's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Guangzhou Baiyunshan could also be used in its relative valuation, which is a method of valuing Guangzhou Baiyunshan by comparing valuation metrics of similar companies.Guangzhou Baiyunshan is currently under evaluation in cash and equivalents category among its peers.
Guangzhou Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0356 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 5.35 B | |||
| Shares Outstanding | 219.9 M | |||
| Shares Owned By Institutions | 34.00 % | |||
| Price To Earning | 8.09 X | |||
| Price To Book | 1.07 X | |||
| Price To Sales | 0.1 X | |||
| Revenue | 69.01 B | |||
| Gross Profit | 13.19 B | |||
| EBITDA | 5.46 B | |||
| Net Income | 3.72 B | |||
| Cash And Equivalents | 21.69 B | |||
| Cash Per Share | 13.34 X | |||
| Total Debt | 752.81 M | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 1.64 X | |||
| Book Value Per Share | 19.33 X | |||
| Cash Flow From Operations | 5.67 B | |||
| Earnings Per Share | 0.33 X | |||
| Number Of Employees | 25.44 K | |||
| Beta | 0.7 | |||
| Market Capitalization | 6.7 B | |||
| Total Asset | 66.12 B | |||
| Z Score | 5.8 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 66.12 B | |||
| Last Dividend Paid | 0.69 |
About Guangzhou Baiyunshan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Guangzhou Baiyunshan Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Guangzhou Baiyunshan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Guangzhou Baiyunshan Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Guangzhou Stock
Guangzhou Baiyunshan financial ratios help investors to determine whether Guangzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Guangzhou with respect to the benefits of owning Guangzhou Baiyunshan security.